A novel multiplex RNAi therapy simultaneously targets *Hif1a* and *Hif2a* to defy retinal degeneration in two models of AMD

Lynn J. A. Ebner[1,2], Cornelia Imsand[1], Duygu Karademir[1,3], Florian Peters[1,4], Eva Kiessling[1,5], Antonia Fottner[1], Claudia Matter[1], Diego S. Fajardo[6], Luca Merolla[1], Gabriele M. Wögenstein[1], Ioanna Tsioti[1], Larissa P. Govers[1], Frank Blaser[7], Isabelle Meneau[7], Sanford L. Boye[6], Shannon E. Boye[8], Christian Grimm[1,+], Marijana Samardzija[1,*,+]

[1] Laboratory for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, Schlieren, 8952, Zurich, Switzerland.

[2] Present address: Roche Pharma Research and Early Development, Roche Innovative Center, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, 4070, Basel-Stadt, Switzerland (lynn.ebner@roche.com)

[3] Present address: Institute of Molecular and Clinical Ophthalmology Basel, Switzerland

[4] Present address: Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland

[5] Present address: Lonza AG, Rottenstrasse 6, 3930 Visp, Switzerland

[6] Department of Pediatrics, Powell Gene Therapy Center, University of Florida; Gainesville, FL, USA.

[7] Department of Ophthalmology, University Hospital Zurich, Switzerland

[8] Department of Pediatrics, Division of Cellular and Molecular Therapy, University of Florida, Gainesville, Florida, USA

[+] Equal contributions

[*] Corresponding author

lynn.ebner@roche.com
dallo.imsand@bluewin.ch
duygu.sigurdsson@iob.ch
florian.peters@usb.ch
eva.kiessling@lonza.com
antonia.fottner@usz.ch
Claudia.matter@usz.ch
diegof@ufl.edu
luca.merolla@uzh.ch
gabriele.woegenstein@uzh.ch
ioanna.tsioti@uzh.ch
larissa.govers@uzh.ch
frank.blaser@usz.ch
isabelle.meneau@usz.ch
sboye@ufl.edu
shaire@ufl.edu
cgrimm@opht.uzh.ch
marijana.samardzija@usz.uzh.ch

Abstract

Age-related tissue changes lead to reduced oxygen delivery to photoreceptors and the retinal pigment epithelium (RPE), and contribute to the pathology of age-related macular degeneration (AMD). The implication of hypoxia-inducible factors (HIFs) in this process makes them good candidates as therapeutic targets for AMD. We developed a multiplex dual-acting therapy utilizing the shRNAmir system, delivered by a single AAV, that reduces mRNA levels of *Hif1a* in photoreceptors and *Hif2a* in the RPE. This RNA interference-based strategy demonstrated a strong therapeutic effect, potently preserving photoreceptors and the RPE in two models of pseudo- and true hypoxia up to 61 weeks post-injection. The efficacy of our dual-acting virus proved superior to single-acting viruses targeting only *Hif1a* in photoreceptors or *Hif2a* in the RPE. By targeting a common, conserved disease pathway, this gene-agnostic RNAi therapy shows significant potential to protect tissues from chronic hypoxic insults in complex diseases such as AMD.

Keywords:

Hypoxia; HIF1; HIF2; retinal degeneration; age related macular degeneration; photoreceptor; retinal pigment epithelium; gene therapy; cell specific RNA interference; AAV; multiplex RNAi

Background

Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly worldwide, primarily affecting the photoreceptors and the retinal pigment epithelium (RPE) in the macular region. These cells degenerate as the disease progresses, leading to reduced visual acuity and eventually central vision loss. Current therapeutic strategies largely focus on targeting secreted pro-angiogenic proteins involved in disease progression. However, emerging RNA-based therapeutics hold considerable promise as alternatives, offering the potential to provide more effective treatments by targeting intracellular pathways that are otherwise difficult to drug [1].

Age-related tissue changes such as reduced choroidal thickness, vascular density and blood flow, ghost vessel formation, thickening of Bruch's membrane and accumulation of drusen deposits [2-5] lead to reduced tissue oxygenation and increased VEGFA secretion, an established driver of neovascularization in the exudative (wet) form of AMD. Notably, these age-related tissue changes may also be relevant to the non-exudative (dry) form of AMD, as they have been correlated with drusen formation [2-5] and suggested to precede photoreceptor or RPE degeneration [6].

Given the critical role of hypoxia-inducible factors (HIFs) in the cellular response to low oxygen levels, chronic activation of the HIF pathway may contribute significantly to the development of AMD. While chronic activation of HIF2, but not HIF1, in the RPE causes RPE atrophy and retinal thinning [7], constitutively active HIF1, but not HIF2, in photoreceptor cells induces photoreceptor degeneration in animal models of AMD [8,9]. Because cell loss and degeneration

81 can be prevented by the genetic inactivation of *Hif1a* in photoreceptors [8,9] and *Hif2a* in the
82 RPE [7], a targeted therapy to reduce the expression of the respective HIF isoform in the two
83 cell types may be an effective approach to manage disease pathology and preserve vision in
84 AMD patients.

85 The need to target two distinct genes in two different cell types presents a unique challenge in
86 developing an effective therapy. To meet this challenge, we have combined an RNA
87 interference (RNAi) strategy with the adeno-associated virus (AAV) delivery system that allows
88 targeted and long-lasting expression of therapeutic genes in retinal cells. Conventional
89 therapeutic RNA knockdown strategies using small interfering RNAs (siRNAs) are often limited
90 because they interfere with endogenous microRNA biogenesis, lead to an overload of transport
91 proteins, or cause other undesirable side effects [10-12]. To circumvent such problems, we have
92 generated a multiplex RNAi approach using the microRNA-based shRNAmir system, which
93 directs the therapeutic RNAs into the miRNA pathway already at the level of DROSHA in the
94 cell nucleus [13,14]. Sequential processing by DROSHA and DICER ensures the generation of
95 precisely cleaved siRNAs while minimizing interference with the natural microRNA processing
96 machinery [14]. This increases efficiency while reducing off-target effects and immune responses
97 [15,16]. The use of the miR-E instead of the conventional miR-30 backbone for shRNA expression
98 increases the knockdown efficiency of target genes and allows cell type specific expression
99 when placed in the 3'UTR of genes that are controlled by Pol-II promoters [17]. Using this system,
100 we developed a novel dual-acting RNA-based therapy that simultaneously targets *Hif1a* in
101 photoreceptors and *Hif2a* in the RPE, delivered by a single AAV. The strong and long-lasting
102 therapeutic potential of this system was demonstrated in two hypoxia-related animal models
103 of AMD.

104

105 # Methods

106 ## Animals

107 Animal experimentation was approved by the Cantonal Veterinary Office of Zürich, Switzerland
108 (license numbers: ZH019/2019 and ZH105/2022) and adhered to the ARVO statement for the
109 use of Animals in Ophthalmic and Vision Research. Wild type (B6/J-Crl1*)* and transgenic mice
110 were maintained as breeding colonies at the Laboratory Animal Service Center (LASC) of the
111 University of Zürich with a 14/10 h light-dark cycle with an average light intensity of 60-150 lux
112 at cage level. Mice had access to food and water *ad libitum*. *Vhl*$^{fl/fl}$ mice [18] were mated to *Vhl*$^{fl/fl}$
113 mice heterozygous for OpsinCre (LMOPC1, [19]) to generate *Vhl*$^{fl/fl}$*;OpsinCre* (*Rod*$^{\Delta Vhl}$) mice and
114 *Vhl*$^{fl/fl}$ control littermates as described (Lange et al., 2011). *Vegfa*$^{fl/fl}$ animals were kindly
115 provided by Christian Stockmann, Institute of Anatomy, University of Zürich [20]. Individual eyes
116 of mice of both sexes were randomly assigned to treatment or control.

117 ## Human tissue samples

118 Human donor eyes without cornea and lens were received from the eyebank of the University
119 Hospital Zürich in ice-cold PBS. The use of the tissue for research was approved by the ethics
120 committee of Zürich, Switzerland (BASEC-Nr: PB_2017-00550 and 2020-01856) and adhered
121 to the tenets of the Declaration of Helsinki. The summarized donor information is given in Table
122 S1. The vitreous was carefully removed and four incisions were used to flatmount the tissue.
123 Retinal and RPE samples were collected from the donor eyes with no clinical diagnosis of
124 retinal disease. RNA was isolated from the samples using the RNeasy kit (Qiagen, Hilden,
125 Germany). cDNA synthesis and real-time PCR were performed using human specific primer
126 pairs (Table 1), following the same methods as described for the mouse samples (see below).

127 **Cloning and generation of AAVs**

128 shRNAmir DNA fragments containing *shHif1a*, *shHif2a* or *shCtrl* sequences were designed
129 using the miR-E backbone following the recommendation by Fellmann *et al.* [17] (Fig. S1A-C)
130 and produced by Bio-Synthesis (Bio-Synthesis Inc. TX, USA). The *shHif1a* and *shHif2a*
131 RNAmiR fragments were cloned into the 3'UTRs of GFP and mCherry, respectively. To
132 achieve cell-specificity, the G-protein-coupled kinase 1 (GRK1) promotor was used for
133 expression of GFP (and thus *shHif1a*) in photoreceptors, and the vitelliform macular dystrophy
134 2 (VMD2, alias bestrophin 1) promoter for expression of mCherry (and thus *shHif2a*) in the
135 RPE. This dual-acting viral construct is named shHif from here on (Fig. 2D). The shCtrl
136 construct had a scrambled shRNA sequence cloned into the miR-E backbone in the 3'UTRs
137 of both fluorescent genes (Fig. 2D). The complete plasmid sequences of plasmids *'shHif'* and
138 *'shCtrl'* are given in supplemental data SD1. Plasmids for the single-acting AAVs contained
139 either the GRK1-GFP-shHif1a or the VMD2-mCherry-shHif2a cassette (Fig. 2D). shHif*,* shHif1*,*
140 shHif2 and shCtrl viruses were packed into an AAV8 with the three mutations Y447F, Y733F
141 and T494V (AAV8-TM) [21]. AAV4::VMD2-Cre-P2A-GFP [22] was used to knockout *Vegfa* in the
142 RPE of *Vegfa*$^{fl/fl}$ mice and AAV4::VMD2-GFP served as control virus. Specifics of all AAVs are
143 provided in Table 2. All AAVs had type 2 ITRs and were produced by the Viral Vector Facility
144 of the University of Zürich.

145 **Subretinal injections**

146 Injections were performed between post-natal days (PND) 27-30 as described by Gasparini et
147 al [23]. Briefly, pupils were dilated with 1% cyclogyl (Alcon Pharmaceuticals, Fribourg,
148 Switzerland) and one drop of 5% neosynephrin (Ursapharm Schweiz GmbH, Hünenberg,
149 Switzerland), and corneas were kept moist with viscotears (Bausch & Lomb Swiss AG, Zug,
150 Switzerland). Mice were anesthetized with a subcutaneous injection of ketamine (85 mg/kg,
151 Parke-Davis, Berlin, Germany) / xylazine (10 mg/kg, Bayer AG, Leverkusen, Germany) and
152 placed on a heating pad set to 37°C during the procedure. The head was held by a stereotactic

153 adapter (Hugo Sachs Elektronik – Harvard Apparatus GmbH, March-Hugstetten, Germany)
154 and the temporal sclera punctured with a 30G needle just beneath the ora serrata. A 5 µL
155 Hamilton syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland), placed in a micromanipulator
156 (H. Saur Laborbedarf, Reutligen, Germany), was inserted gently through the pre-punctured
157 site for transvitreal subretinal injections of 1 µL AAV solution approximately 15-25° nasally of
158 the optic nerve. All AAVs were applied at a concentration of $5x10^8$ vg/µL, except for
159 AAV4::VMD-Cre-P2A-eGFP ($1x10^9$ vg/µL) when used to generate *RPE*$^{\Delta Vegfa}$ mice for
160 characterization (Fig. 4). To visualize and control injections, the injection solution was
161 supplemented with 10% fluorescein (0.1 mg/mL, Akorn Inc., IL, USA). After injections,
162 anesthesia was reversed with atipazemole (2 mg/kg, Graeub, Bern, Switzerland) and mice
163 were placed on a heating pad until fully awake.

164 **Funduscopy, optical coherence tomography, angiography, and volume scans**

165 Anesthesia and pupil dilation were performed as described above. One drop of 2% methocel
166 (OmniVision AG, Neuhausen, Switzerland) was applied to keep the eyes moist. Fundus
167 images and optical coherence tomography (OCT) scans were acquired using the Micron IV
168 system (Phoenix Research Labs, Pleasanton, CA, USA) as described [24]. For fluorescein
169 angiography mice were injected intraperitoneally with 30 µL of 2% fluorescein (Akorn Inc., IL,
170 USA) and retinal vasculature was imaged with the Micron IV system. For *in vivo* quantification
171 of retinal thickness, volume scans were performed using a Spectralis OCT-2 device
172 (Heidelberg Engineering Inc., Heidelberg, Germany) with a 25-diopter lens. Animals were
173 placed on a custom-built holder and kept warm with an integrated water heating system. An
174 atraumatic focal contact lens was placed on the cornea moistened with a drop of viscotears
175 (Bausch & Lomb) to improve imaging quality. The optic scan area was aligned to the optic
176 nerve head and 25 consecutive high-resolution B-scans, each consisting of 1024 A-scans,
177 were acquired. Automatic real-time tracking was set to 50. The built-in semi-automated
178 segmentation tool (Spectralis software version 6.7.13.0, Eye Explorer software version

179 1.9.14.0) was utilized, and manual adjustments were done by blinded, experienced users (L.E.,
180 C.I., M.S.) to measure outer nuclear layer (ONL) thickness *in vivo*. To delineate fundus areas,
181 an Early Treatment Diabetic Retinopathy Study (ETDRS) circular grid with 9 subfields (1, 2.22,
182 3.45) was aligned to the optic nerve head (ON). ONL thickness was quantified in two ($RPE^{\Delta Vegfa}$
183 mice) or seven subfields ($Rod^{\Delta Vhl}$ mice). These subregions were marked with orange outlines
184 in the respective images. For quantification, the data were first averaged per subfield using
185 ETDRS grids (left), then the average across all subfields was calculated and plotted for each
186 eye (graphs, right).

187 **Scotopic and photopic electroretinogram**

188 Mice were dark-adapted overnight. Pupils were dilated and animals anesthetized as described
189 above. Electroretinograms (ERG) were recorded simultaneously from both eyes using the
190 Diagnosys Celeris rodent ERG device (Diagnosys, Cambridge, UK). Stimulus intensities
191 ranging from $8x10^{-6}$ to 3 cd*s/m^2 were used for scotopic measurements. After a 5-min exposure
192 to rod-suppressive background light (30 cd/m^2), photopic recordings were acquired using
193 single-flash intensities ranging from 1 to 200 cd*s/m^2 with the background light on. For each
194 stimulus intensity, five traces were averaged under scotopic and ten traces under photopic
195 conditions.

196 **RNA isolation and real-time PCR**

197 Mice were euthanized with CO_2 inhalation followed by decapitation. Retinas were isolated
198 through a slit in the cornea and snap-frozen in liquid nitrogen. In some instances, the remaining
199 eyecup (EC) containing the RPE was cleaned from excessive tissue including the cornea and
200 snap-frozen. RNA from tissues or cells was isolated using an RNA isolation kit (NucleoSpin
201 RNA, Macherey-Nagel GmbH & co.KG, Düren, Germany) according to the manufacturer's
202 instructions, including a DNase digestion step on the column. First-strand cDNA synthesis was
203 performed by M-MLV reverse transcriptase (Promega, Dübendorf, Switzerland) using 1 µg

204 total RNA and oligo-dT primers. Gene expression was analyzed via semi-quantitative real-time
205 PCR (QuantStudio 3, Thermo Fisher Scientific, MA, USA) using 10 ng of cDNA template and
206 PowerUp SYBR green Master Mix (Thermo Fisher Scientific). Primers pairs (Table 1) were
207 designed to span large intronic regions and avoid known single nucleotide polymorphisms in
208 the mouse sequence. Normalization was performed with β-Actin (*Actb)* as housekeeping gene,
209 and relative expression was calculated using the comparative threshold cycle method ($2^{-\Delta\Delta CT}$)
210 [25].

211 **Morphology and immunofluorescence**

212 Morphology and immunofluorescence analyses were performed as described [26]. For
213 morphology, dorsally marked eyes were enucleated from non-perfused ($Rod^{\Delta Vhl}$) or perfused
214 ($RPE^{\Delta Vegfa}$; 4% paraformaldehyde (PFA)) mice and subsequently fixed in 2.5% glutaraldehyde
215 at 4°C overnight. Eyes were postfixed in 1% osmium tetroxide and embedded in Epon812.
216 Nasal-temporal sections (0.5 µm) were cut through the optic nerve head, counterstained with
217 toluidine blue, and analyzed by light microscopy (AxioImager Z2, Carl Zeiss AG, Feldbach,
218 Switzerland). ONL thickness and photoreceptor segment (PS) length were measured every
219 200 µm (from the optic nerve head) along reconstructed panorama images using Adobe
220 Photoshop CS6 ruler tool (Adobe Systems, Inc.).

221 Eyes for immunofluorescence analysis were labelled dorsally and fixed in 4% PFA for 1 h.
222 After removal of the lens and post-fixation for an additional hour, eyes were cryoprotected in
223 30% sucrose (Sigma-Aldrich, St. Louis, MO, USA) overnight, embedded and frozen in freezing
224 medium (O.C.T., Leica Biosystems, Nussloch, Germany). Eyes were stored at -80°C until
225 sectioned into 12 µm thin nasal-temporal sections. Immunolabelling was performed overnight
226 at 4°C with primary antibodies (Table 3) in blocking solution containing 3% normal goat serum
227 (Sigma-Aldrich) and 0.3% Triton X-100 (Sigma-Aldrich) in phosphate buffer. On the next day,
228 sections were washed and incubated with the appropriate secondary antibodies in blocking
229 solution for 1 h. Counterstaining was done with 4',6-diamidino-2-phenylindole (DAPI) before

230 sections were mounted with MOWIOL (Sigma-Aldrich) antifade medium and imaged using a
231 fluorescence microscope (AxioImager Z2, Carl Zeiss AG). Pixel intensity measurements were
232 performed using ImageJ (Version 1.52a) by analyzing 250 µm long regions within transduced
233 and non-transduced areas. The automatic threshold function was used to identify signal and
234 background pixels. Pixels with an intensity of '0' were counted as background/gaps. The
235 cumulative length of these zero-intensity regions was calculated and presented as gap size
236 per 250 µm.

237 ***In-situ* hybridization**

238 *In-situ* hybridization was performed with the RNAscope 2.5 HD RED Detection Kit (Cat. No.
239 322350, BioTechne/ACD, Minneapolis, USA). Cryosections were prepared as described
240 above, baked at 60°C for 30 min, and post-fixed in 4% PFA for 15 min at 4°C. Slides were
241 dehydrated for 5 min each in 50%, 70% and 100% ethanol and dried for 10 min at 60°C.
242 Antigen retrieval was performed using hydrogen peroxide for 10 min, washed and followed by
243 overnight incubation with target retrieval buffer (BioTechne/ACD). Protease Plus treatment
244 was performed for 15 min at 40°C, followed by 2 x 30 s washings with H_2O, and incubation
245 with probes (Mm-Hif1a Cat. No. 313821, Mm-Epas1 Cat. No. 314371, Mm-Vegfa-O3 Cat. No.
246 521471; BioTechne/ACD) for 2 h at 40°C. Hybridized tissue sections were washed 2 x 5 min
247 with wash buffer and incubated at 40°C with each amplifier (1-6) for 15-30 min, with two 5-
248 minute washes conducted between each amplification step. The positive control probe *Mm-*
249 *Polr2a* (Cat. No. 312471, BioTechne/ACD) and the negative control probe diluent (Cat. No.
250 300041, BioTechne/ACD) were used to validate experimental conditions. Slides were stained
251 in 50% hematoxylin for 20 s, destained in H_2O, incubated in 0.02% ammonia water for 10 s,
252 and washed again. Finally, slides were dried for 30 min at 60°C and mounted with Ecomount
253 (Cat. No. 320409, BioTechne/ACD).

254 **Retina- and RPE-flatmounts**

255 After eyes were enucleated and incubated in 4% PFA for 10 min, corneas were opened and
256 eyes incubated for another 20 min in PFA. The eyes were cut along the ora serrata to remove
257 the cornea and placed on a nylon membrane (Boehringer Ingelheim, Ingelheim am Rhein,
258 Germany). 5-6 radial incisions were made to flatten the eyecup and retina, and the lens was
259 removed. Retina and eyecup were then separated and held flat between 2 membranes during
260 an additional hour of fixation in 4% PFA. Flattened retinas or eyecups were removed from the
261 membrane, washed with PBS, and blocked with 3% normal goat serum (Sigma-Aldrich, St.
262 Louis, MO, USA) and 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 1-2 h. Incubation with
263 primary antibodies (Table 3) was overnight at 4°C. Flatmounts were washed 3 x 10 min with
264 PBS and incubated with the appropriate secondary antibodies for 1 h at room temperature.
265 Subsequently, retinas and eyecups were washed 3 x 10 min with PBS, mounted, and imaged
266 using a fluorescence microscope AxioImager Z2 (Carl Zeiss AG) or Leica DMI6000B (Leica
267 Microsystems, Wetzlar, Germany).

268 **Choroidal flatmounts**

269 After an initial 30 min fixation in 4% PFA, eyes for choroidal flatmounts were washed in PBS
270 and incubated at 55°C in pre-warmed 10% H_2O_2 for 2 to 2.5 h to bleach RPE and choroidal
271 pigments. The cornea was removed by cutting along the ora serrata, and the eyes were placed
272 on a nylon membrane. Lens and retina were removed, and four radial incisions were made to
273 flatten the choroidal eyecup. The flattened tissue, secured between 2 nylon membranes,
274 underwent an additional fixation step in 4% PFA for 1 h. Staining for podocalyxin-like (PODXL)
275 proceeded as above, with the modifications that incubation with the primary antibody lasted
276 for 2 days, and 3% horse serum (Sigma-Aldrich) was used for blocking.

277 **Lentiviral-mediated gene silencing in 661W cells and hypoxic exposure**

278 661W [27] and HEK293T (ATCC CRL-3216) cells were cultured in DMEM, 10% heat-inactivated
279 FBS (Gibco, Thermo Fisher Scientific) and 1% penicillin-streptomycin (Gibco, Thermo Fisher
280 Scientific) at 37°C and 5% CO_2. Lentiviral-pseudotyped particles were used to generate stable
281 cell lines expressing shRNA against *Hif1a* (TRCN0000232222) or *Hif2a* (TRCN0000082303,
282 TRCN0000082307, TRCN0000436203, TRCN0000416474, TRCN0000428636,
283 TRCN0000082306) or a non-targeted scrambled shRNA (shCtrl, SHC002) (Sigma-Aldrich). To
284 prepare lentiviral particles, HEK293T cells were seeded in 75 cm^2 culture flasks and co-
285 transfected with shRNAs in combination with the ViraPower lentiviral expression vector system
286 and Lipofectamin 3000 (Invitrogen, Thermo Fisher Scientific) in serum-free medium. Medium
287 was replaced the next day with medium containing FBS. The culture supernatants containing
288 the lentivirus particles were collected 48-72 h post-transfection, cleared by centrifugation at
289 200 g for 5 min, and filtered through a 0.45 µm pore size filter (Merck & Cie, Schaffhausen,
290 Switzerland). Filtrates were applied in a 1:1 mixture with medium containing 6 µg/mL polybrene
291 (Sigma-Aldrich) to infect 661W cells. Infected cells were selected with 2 µg/mL puromycin for
292 2 weeks. Stable cell lines expressing *shHif1a*, *shHif2a,* and *shCtrl* were seeded at a density of
293 30,000 cells/mL in a 6-well plate and incubated overnight. Prior to hypoxic exposure, medium
294 was exchanged, and cells were exposed to normoxia (21% O_2) or hypoxia (0.2% O_2 for 24 h).
295 Subsequently, cells were harvested and prepared for Western blotting (see below) or real-time
296 PCR (see above).

297 **Western blotting**

298 Cells were washed with PBS and lysed with 50 µL lysis buffer (1 M Tris, 150 mM NaCl, 1 mM
299 Na_3VO_4, 1% Triton X-100 containing protease inhibitor (1 tablet per 10 ml solution; cOmplete
300 ULTRA Tablets-Mini, F. Hoffmann-La Roche AG, Basel, Switzerland). Cells were scraped off
301 the plate, homogenized by sonication for 10 min and centrifuged (3 min 1000 rcf) at room
302 temperature. The protein concentration was determined in the supernatant with a BCA protein

303 assay kit (Pierce™, Thermo Scientific) according to manufacturer's instructions. DNA present
304 in the homogenate was digested at 37°C for 1 h with 125 units benzonase (Sigma-Aldrich, St.
305 Louis, MO, USA) before 70 µg of proteins were used for standard Western blotting. Primary
306 antibodies (Table 3) were diluted in 5% non-fat blocking milk (BioRad, Cressier, Switzerland)
307 in TBST and incubated over night at 4°C with mild agitation. HRP-conjugated secondary
308 antibodies were used for signal detection by the Western lightning chemiluminescence reagent
309 (PerkinElmer, Waltham, MA, USA) and exposure to X-ray films.

310 **Statistical analysis**

311 Statistical analysis was performed using GraphPad Prism (GraphPad Software, San Diego,
312 CA, USA). Significance was tested by an unpaired t-test when two independent groups were
313 compared. When more than 2 groups were compared, a one-way ANOVA followed by a
314 Tukey's (when all groups were compared to each other) or Dunnett's (when all groups were
315 compared to a specific group) multiple comparison test was applied. Data were considered to
316 be statistically different with $p \leq 0.05$. P-values are given directly in figures or in Table S2. All
317 tests and number of animals/samples are indicated in the figure legends.

318

319 ## Results

320 Age-related tissue changes impair oxygen delivery to the RPE and photoreceptors leading to
321 a chronic molecular response to hypoxia that can be harmful to these delicate cells in the aging
322 eye. RNA interference may be an ideal therapeutic strategy to attenuate this response and
323 support long-term cell survival. To investigate the impact of ageing on the expression of known
324 hypoxia-regulated genes [28-30] associated with AMD [29,31,32], we determined the expression of
325 *VEGFA*, angiopoietin like 4 (*ANGPTL4*) and serpin family E member 1 (*SERPINE1*) in the
326 retina and RPE of young (17 – 55 y, median: 35 y) and old (71 – 94 y, median: 82 y) human
327 donor eyes (Table S1). G protein subunit alpha transducin 2 (*GNAT2*), a gene essential for
328 phototransduction in cones [33], and retinoid isomerohydrolase RPE65 required for the visual
329 cycle in the RPE [34] were included as controls. The observed increased expression of all three
330 hypoxia-regulated genes, but not of the control genes, in the neuronal retina and the RPE of
331 old donor eyes (Fig. 1) points to an elevated activity of HIF transcription factors with age.
332 Reducing the expression of HIF transcription factors in the retina and RPE by RNA
333 interference may attenuate their activity, reduce the expression of AMD-related HIF target
334 genes and thus provide significant therapeutic benefits.

335 **Efficient targeting of *Hif1a* and *Hif2a* using the shRNAmir system**

336 Chronically active HIF1 is the main driver for degeneration of photoreceptors, while HIF2 is the
337 pathologic isoform in RPE cells [7,8]. To prevent hypoxia-related degeneration, we developed an
338 RNA interference strategy that simultaneously silences HIF1 in photoreceptors and HIF2 in the
339 RPE by targeting the mRNAs for the respective HIF alpha subunits in the specific cell types.
340 To reduce *Hif1a* expression, we used a published and previously validated shHif1a RNA
341 sequence that targets both the mouse and human sequence [8] and refer to this sequence as
342 shHif1. To identify an efficient shHif2a sequence, six different shRNAs (shHif2_1-6) were
343 stably expressed in 661W cells and tested for their efficiency to reduce expression of *Hif2a*.

344 All six shRNAs were similarly efficient and reduced *Hif2a* mRNA levels in hypoxic cells (6 h,
345 0.2% O_2) to 2 - 9% when compared to the shCtrl sequence (Fig. S2). Since mouse shHif2_6
346 has only one mismatch to the human *HIF2A* RNA, all further experiments were performed
347 using this sequence, which will be referred to as shHif2.

348 *Hif1a* and *Hif2a* mRNA and protein levels were measured in normoxic and hypoxic (24 h, 0.2%
349 O_2) 661W cells stably expressing shHif1, shHif2 or shCtrl (Fig. 2B, C). *Hif1a* mRNA expression
350 was reduced by about 65% in both normoxic and hypoxic 661W-shHif1 cells when compared
351 to 661W-shCtrl cells while it remained at control levels in 661W-shHif2 cells (Fig. 2B). *Hif2a*
352 expression was reduced by roughly 80% in normoxic and hypoxic 661W-shHif2 but not 661W-
353 shHif1 cells. Interestingly, an 86% increase in *Hif2a* levels was observed in hypoxic 661W-
354 shHif1 cells, suggesting a compensatory induction of *Hif2a* upon *Hif1a* knockdown in hypoxia,
355 as reported by others [35]. The hypoxic state of the cells was confirmed by the significantly
356 increased expression level of solute carrier 2a1 (*Slc2a1,* alias *Glut1,* Fig. 2B), a gene primarily
357 regulated by HIF1. The diminished but still measurable *Slc2a1* expression levels in hypoxic
358 661W-shHif1 cells indicated a strongly but not fully blocked HIF1 activity, which is expected
359 after robust but not complete *Hif1a* gene silencing (Fig. 2B). Western blots confirmed increased
360 HIF1A and HIF2A protein levels in hypoxic cells and their specific reduction by the
361 corresponding shRNAs (Fig. 2C). Thus, the selected shRNAs efficiently downregulated *Hif1a*
362 and *Hif2a* at both the mRNA and protein levels.

363 To achieve a simultaneous and effective *in vivo* downregulation of *Hif1a* in photoreceptors and
364 *Hif2a* in the RPE, we placed the corresponding shRNAs (Fig. S1) into miR-E scaffolds [17] and
365 positioned them in the 3'UTRs of GFP (shHif1) and mCherry (shHif2). GRK1 [36] and VMD2 [37]
366 promoters were used to drive expression of GFP::miR-E-shHif1 in photoreceptors and
367 mCherry::miR-E-shHif2 in the RPE (Fig. 2D). Using a single vector to deliver the two shRNAs
368 to their specific cell type allowed for an efficient and precise intervention. A scrambled RNA
369 sequence replaced shHif1 and shHif2 in the shCtrl vector. To compare the potency of this

370 multiplex dual-acting AAV with single-acting AAVs, we generated two additional vectors to
371 deliver either shHif1 to the photoreceptors or shHif2 to the RPE (Fig. 2D).

372 **Targeted expression in photoreceptors and RPE of wild type mice**

373 The AAVs carrying shHif or shCtrl were injected into the subretinal space of wild type mice
374 (Fig. 3A) to evaluate transduction and expression profile of delivered constructs. Two weeks
375 after administration, the injection site was visible as a hyperreflective spot in the fundus (Fig.
376 3B,C; arrows). OCT scans taken at the injection site showed minor layer distortions likely
377 attributable to retinal injury caused by needle penetration. Beyond the injection site, however,
378 tissue integrity was preserved in shCtrl- or shHif-treated areas, as shown by OCT scans
379 through the optic nerve head, indicating that neither vector was toxic to retinal cells or the RPE
380 (Fig. 3B,C). Fluorescence funduscopy showed widespread GFP (as surrogate marker for
381 shHif1 expression) and mCherry (indicating shHif2 expression) positive areas surrounding the
382 injection site (Fig. 3B,C). Retinal cross-sections collected at 3 weeks post-injection (wpi)
383 showed GFP and mCherry signals localized to photoreceptors and the RPE, respectively (Fig.
384 3D,E). However, weak mCherry fluorescence was also detected in the neural retina close to
385 the injection site. The signal was much less robust than in the RPE and decreased to
386 undetectable levels with increasing distance from the injection site. Similarly, some GFP
387 fluorescence was observed in the RPE. While this may be attributed to phagocytosis of shed
388 GFP-positive outer segments by RPE cells, we cannot completely rule out expression of the
389 GRK1-driven gene in the RPE, as it has been observed for AAV8 in macaque before [38]. To
390 evaluate the transduction perimeter, GFP and mCherry fluorescence was examined on retinal
391 and RPE flatmounts at 3 wpi. The GFP-positive area covered approximately 40-50% of the
392 total retina and closely matched the mCherry-positive area in the corresponding RPE both in
393 size and position (Fig. 3F,G). Together with the reduced levels of *Hif1a* in photoreceptors and
394 *Hif2a* in the RPE in the transduced area (Fig. S3A,B), this demonstrates successful reduction
395 of the target mRNAs in the intended cell types. Potential inflammation was assessed by

396 immunofluorescence staining for allograft inflammatory factor 1 (IBA1, alias AIF1) on retina
397 and RPE flatmounts, and in retinal cross-sections at 3 wpi (Fig. 3F,G, Fig. S3C). Whereas
398 reactive (amoeboid) microglia and/or macrophages were detected in the retina close to the
399 injection site, ramified resting microglia populated the surrounding tissue. RPE flatmounts
400 presented few IBA1-positive cells only close to the injection site. The presence of microglia or
401 macrophages in this restricted area might have been caused by retinal detachment and scar
402 formation inflicted by the subretinal injections. Apart from the perturbations at the injection site,
403 the transduced areas showed normal staining patterns for cone arrestin (ARR3) and beta-
404 catenin (CTNB1) (Fig. S3D), and showed no signs of degeneration or functional impairment
405 up to 22 wpi (Fig. 3H,I; Fig. S3E). Taken together, these results demonstrate widespread and
406 selective transduction of photoreceptors and RPE cells by the AAV delivering the multiplex
407 RNA therapeutics with no apparent adverse effects beyond the injection site.

408 **Mouse models for AMD**

409 Our therapeutic strategy centers on targeting the alpha subunits of HIF1 and HIF2 transcription
410 factors, which are stabilized under reduced oxygen levels. Stabilization is initiated when the
411 activity of HIF-prolyl hydroxylases decreases due to reduced availability of O_2 as substrate.
412 Reduced hydroxylation of HIF1A and HIF2A prevents their recognition by the VHL protein
413 complex and subsequent degradation by proteasomes allowing them to accumulate and
414 function as transcription factors. This accumulation (and activation) of HIF1 and HIF2 is
415 mimicked in *Rod*$^{\Delta Vhl}$ mice, which lack VHL in rods. These mice represent a pseudohypoxia
416 model in which the hypoxic response is elicited in the presence of normal oxygen levels leading
417 to photoreceptor degeneration [8,9]. The stabilization of HIF1A by the chemical prolyl
418 hydroxylase inhibitor rodaxustat resulted in comparable cell death [39] supporting the validity of
419 the model. However, eyes of ageing individuals and those afflicted by AMD experience hypoxia
420 affecting both photoreceptors and the RPE. Thus, we established a second model by knocking
421 out *Vegfa* in RPE cells of adult mice (*RPE*$^{\Delta Vegfa}$; Fig. 4A). As reported by others, the lack of

422 VEGFA disrupts the homeostasis in the choriocapillaris leading to vasoconstriction in the
423 choroid. This results in the development of true hypoxic conditions, including HIF activation,
424 consequently causing RPE and photoreceptor degeneration [7,40,41]. To generate a local
425 phenotype, we delivered Cre recombinase to the nasal RPE of 28-day-old *Vegfa*$^{fl/fl}$ mice [20] by
426 the subretinal injection of an AAV4 expressing Cre-P2A-eGFP under control of the VMD2
427 promoter (Table 2). Inactivation of *Vegfa* expression in the transduced RPE was verified by *in*
428 *situ* hybridization, and transduction was confirmed by staining for Cre in the consecutive
429 section at 3 wpi. *Vegfa* expression was evident in the non-transduced area but absent in Cre-
430 positive RPE cells in the transduced area (Fig. 4B). This mutually exclusive expression pattern
431 indicated an effective suppression of *Vegfa* in transduced RPE cells. Choroidal flatmounts
432 stained for podocalyxin (PODXL), an endothelial cell marker, demonstrated a strong reduction
433 of choroidal vessel density at 3 wpi (Fig. 4C). To quantify the phenotype, we analyzed the
434 staining pattern of PODXL in sections through control and transduced regions lacking *Vegfa*
435 expression. Transduced areas showed notable gaps in the PODXL pattern and a significant
436 increase in the gap size (Fig. 4C), suggesting a collapse of the choriocapillaris and
437 rearrangement of endothelial cells in the absence of RPE-derived VEGFA.

438 At 3 wpi the transduced area was clearly visible as a brighter region in the fundus that
439 correlated with the GFP-positive area and thus expression of Cre (Fig. 4D). Angiography
440 indicated a predominantly regular retinal vasculature, and OCT showed normal retinal
441 thickness, with the expected small perturbations around the injection site at this time (Fig. 4D,
442 upper panel). At 39 wpi, however, the same eye presented various abnormalities including
443 fundus discoloration, RPE hypertrophy, retinal thinning with an almost complete loss of the
444 ONL and vascular leakage (Fig. 4D-F; Fig. S4). The weak GFP signal (Fig. 4D) suggested
445 either a loss of transgene expression or the death of transduced cells at this time point. To
446 quantify the effect *in vivo*, we employed OCT volume scans and measured the ONL thickness
447 in two nasal subfields. Direct comparisons showed a significantly reduced ONL thickness in
448 *RPE*$^{\Delta Vegfa}$ but not in non-injected (*Vegfa*$^{fl/fl}$) or control-injected (*Vegfa*$^{fl/fl}$ *+PBS or +GFP)* mice

449 (Fig. 4E). Light microscopy and quantification of equatorial nasal-temporal sections supported
450 the *in vivo* findings and revealed significant thinning of the ONL and reduced length of PS that
451 was restricted to the transduced nasal retina of *RPE*$^{\Delta Vegfa}$ mice (Fig. 4F,G). The phenotype was
452 not caused by subretinal injections or the activity of the VMD2 promotor *per se* since the
453 respective controls showed no signs of retinal degeneration (Fig. 4F,G).

454 **Dual-acting shHif therapy restores tissue integrity in *Rod*$^{\Delta Vhl}$ mice**

455 Having validated the expression pattern of the shHif AAV vector in wt mice (Fig. 3), we
456 proceeded to investigate whether this vector can effectively interfere with the hypoxia pathway
457 in our two mouse models. We first used the *Rod*$^{\Delta Vhl}$ mouse with its chronically activated
458 molecular response to hypoxia in rod photoreceptors due to the rod-specific deletion of *Vhl*
459 (Fig. 5A). The model is characterized by a HIF1-dependent, late onset progressive loss of
460 photoreceptors, occasional disturbances in the RPE, and a decline in visual function [8,9]. As
461 expected, untreated 26-week-old *Rod*$^{\Delta Vhl}$ mice showed patches of photoreceptor cell loss in
462 the fundus, as well as RPE and photoreceptor irregularities in OCT images (Fig. 5B). Age-
463 matched *Rod*$^{\Delta Vhl}$ mice injected with shCtrl vector displayed a comparable phenotype at 22 wpi,
464 with patches of degenerated areas in normal fundus that were prominently visible as dark
465 flecks in fundus fluorescence images capturing vector-derived GFP and mCherry signals. In
466 contrast, fundi and OCT images of shHif-treated mice displayed fewer irregularities and no
467 obvious signs of RPE disturbances (Fig. 5B). To quantify the extent of rescue *in vivo*, we
468 measured ONL thickness in the different groups using volumetric OCT scans. Although not
469 reaching the thickness of control *Vhl*$^{fl/fl}$ mice (without Opsin-Cre), treatment of *Rod*$^{\Delta Vhl}$ mice
470 with shHif resulted in a significantly thicker ONL compared to *Rod*$^{\Delta Vhl}$ mice treated with shCtrl
471 (Fig. 5C). Light microscopy of retinal morphology at 22 wpi supported these findings and
472 showed that retinal areas that had received the shHif virus had less severe ONL thinning and
473 RPE disturbances than non- or shCtrl-transduced areas (Fig. 5D).

474 Gene expression analysis at 22 wpi showed reduced *Hif1a* but not *Hif2a* mRNA levels in the
475 retina, (Fig. 5E) and reduced *Hif2a* but not *Hif1a* mRNA expression in the eyecup tissue that
476 included the RPE (Fig. 5F). This suggests a high degree of cell-type specificity of our dual-
477 acting shHif gene silencing approach. The rather moderate reduction of the respective
478 expression levels of *Hif1a* and *Hif2a* by only 20-30% was not surprising because tissue
479 samples used for these experiments also contained cells from the transduced area that were
480 not targeted by our vector (e.g. 2nd and 3rd order neurons) and cells from non-transduced areas.
481 This may also be the reason why levels of *Casp1* (marker for degenerative processes) and
482 *Pde6b* (marker for rod integrity) in the retina and of *Rpe65* (marker for RPE integrity) in the
483 eyecup were only slightly reduced or increased, respectively (Fig. 5E). Together with the
484 significant rescue of retinal thickness our gene expression data collectively supports a
485 considerable potential of the shHif approach for alleviating the harmful effects of a chronic
486 hypoxic response in photoreceptors.

487 **Dual-acting shHif therapy restores tissue integrity in *RPE$^{\Delta Vegfa}$* mice**

488 We proceeded to assess the potential of the shHif approach to mitigate the degenerative
489 effects of true chronic hypoxia in the *RPE$^{\Delta Vegfa}$* model. Since this model also includes the
490 pathogenic activation of HIF2A in the RPE [7], we compared the efficacy of the dual-acting shHif
491 AAV with single-acting shHif1 (targeting photoreceptors) and shHif2a (targeting the RPE)
492 AAVs. Subretinal co-injections of AAV::VMD2-Cre-P2A-eGFP to inactivate *Vegfa* in the RPE,
493 along with either shCtrl, shHif, shHif1 or shHif2 were performed at 4 weeks of age followed by
494 analysis at 39 wpi. Funduscopy and OCT of *RPE$^{\Delta Vegfa}$* mice injected with shCtrl showed
495 discolored patches and affected tissue layers, indicating RPE disturbances and degeneration
496 at 39 wpi (Fig. 6A), a phenotype similar to untreated *RPE$^{\Delta Vegfa}$* mice (Fig 4D). In contrast, shHif-
497 treated animals displayed only minor disturbances around the injections site, but no obvious
498 retinal degeneration (Fig. 6A). The rescue effect by the treatment with the various viruses was
499 quantified *in vivo* using OCT volume scans. Treatment with the dual-acting shHif virus

500 preserved ONL thickness in *RPE*$^{\Delta Vegfa}$ mice significantly better than treatment with the single-
501 acting or control AAVs. (Fig. 6B). The superior rescue effect by shHif was further verified by
502 light microscopy of retinal sections (Fig. 6C) and measurements of ONL thickness and PS
503 length (Fig. 6D) in a subset of mice. Eyes treated with shCtrl displayed a drastic thinning of the
504 ONL, loss of PS, and variable thickness of the RPE in transduced areas. In contrast, mice
505 treated with shHif had preserved PS with few disturbances, a thicker ONL, and only sporadic
506 regions with irregular RPE morphology. shHif1 and shHif2 viruses rescued the phenotype at
507 intermediate levels (Fig. 6C,D). Areas that were not transduced by the Cre-expressing virus
508 and thus with regular *Vegfa* expression in the RPE showed normal retinal morphologies for all
509 injected eyes. The superior rescue effect by the dual-acting shHif virus underscores the
510 importance of simultaneously targeting Hif1 in photoreceptors and Hif2 in the RPE to efficiently
511 mitigate the consequences of chronic hypoxia. The dual-targeting approach was not only
512 superior to targeting individual HIF transcription factors but was also long lasting and protected
513 tissue integrity at least up to 61 wpi (Fig. 7). While *RPE*$^{\Delta Vegfa}$ mice treated with shCtrl exhibited
514 significant loss of GFP and mCherry fluorescence at 61 wpi when compared to 4 wpi, shHif
515 treated mice still showed strong fluorescence at this time point suggesting preservation of
516 photoreceptors and RPE (Fig. 7A,B). This was confirmed by light microscopy of retinal sections
517 and quantification of ONL thickness and PS length which showed strong preservation of retinal
518 morphology in shHif but not shCtrl treated mice (Fig 7C,D). The eyes injected with the GFP
519 control virus provided a baseline for non-degenerated retinas allowing to assess the overall
520 efficacy of the dual-acting shHif virus. Our results demonstrate the efficacy of our multiplex
521 shHif therapy in preserving retinal structures for more than one year despite the continued
522 presence of the toxic hypoxic stimulus. The strong protection in two different models of
523 hypoxia-induced retinal degeneration indicates the potential of the approach for a future
524 translation into a clinical setting.
525

526 ## Discussion

527 Age is the major non-genetic risk factor for the development of AMD. The aging ocular tissue
528 undergoes several changes that result in reduced oxygen levels in the outer retina and
529 increased expression of HIF target genes [2,3,8]. Some HIF target genes, such as *VEGFA* and
530 *ANGPTL4*, are angiogenic factors that ultimately contribute to the development of neovascular
531 AMD [29,32]. Others, such as *SERPINE1*, may facilitate disease development by remodeling the
532 extracellular matrix [31] or through their connection to senescence and ageing [42]. Notably, the
533 expression of all three aforementioned hypoxia-related and AMD-associated genes was
534 increased in old donor eyes.

535 An integral part of the development and utilization of this therapy is that the nature of the retinal
536 disease must be considered when targeting the hypoxia pathway as a gene-agnostic
537 therapeutic approach, since a hypoxic environment triggers an intracellular response that
538 adjusts major metabolic pathways, including glycolysis, oxidative phosphorylation, lipid
539 metabolism, and others, to the new environmental conditions. This metabolic shift may reduce
540 the susceptibility of photoreceptors to mutation-induced degeneration [43], but seems to
541 contribute to cell death in otherwise normal photoreceptors and cells of the RPE. This divergent
542 reaction of mutant and normal cells to an activated hypoxic response highlights the complex
543 interplay between cell metabolism, aging, hypoxia, and other pathways involved in inherited
544 retinal degeneration or AMD development [7,8,43-46]. In the case of AMD, reducing the HIF
545 pathway may be favorable and benefit a wide range of patients affected by either the wet or
546 dry form of the disease.

547 Here we established an efficient RNA interference strategy that simultaneously targets HIF1
548 in the photoreceptors and HIF2 in the RPE. This multiplex approach prevented retinal
549 degeneration connected to a chronic hypoxic response in two mouse models of pseudo- or
550 true hypoxia. Another key finding was the demonstration that this dual-acting therapy proved

551 to be more effective than single-target treatments. This finding highlights the potential and
552 superiority of multi-target therapies for complex multifactorial diseases such as AMD.

553 The use of shRNAs driven by Pol II promoters to downregulate target genes has several
554 advantages. (i) It allows targeting only those cell types that require treatment without affecting
555 other cells. (ii) It does not completely inactivate the target genes allowing their activity for
556 essential or housekeeping tasks, in contrast to knockout strategies. (iii) It ensures long-lasting
557 effects through continuous expression of the therapeutic RNAs as opposed to the transient
558 effects of short-lived synthetic siRNAs. (iv) It minimizes the possibility that a bolus injection of
559 siRNAs will overwhelm the endogenous RNAi pathway leading to toxic side effects [16,47].
560 Because our multiplex system is based on a single AAV vector, it has the additional advantage
561 that it does not rely on double transduction of individual cells, trans-splicing, or other
562 mechanisms that may reduce efficiency. The therapeutic approach is not only well tolerated,
563 but also potent and has protected tissue integrity for up to 61 weeks in two different models of
564 hypoxia-related retinal degeneration that share key aspects of AMD.

565 In contrast to our data for the chronic models presented here, the recent work of Babapoor-
566 Farrokhran and colleagues suggests a beneficial function of HIF1 for the survival of wild type
567 photoreceptors [48]. However, this conclusion was drawn after the induction of acute oxidative
568 stress by $NaIO_3$, which may less accurately model the effects of a long-lasting chronic hypoxic
569 response or environment. In addition, the chemicals used in their study can be toxic to
570 photoreceptors *per se* (digoxin; [49]) or exhibit side effects apart from HIF activation (DMOG;
571 [50,51]). Nevertheless, data from their acute model is interesting and may best be correlated with
572 the protective effects of hypoxic preconditioning against acute light-induced retinal
573 degeneration [52]. Since this indicates that acute and chronic hypoxic responses have distinct
574 consequences for retinal cells, we believe that our two genetic models for chronic hypoxia
575 represent the situation in the aged eye more accurately than drug-induced acute models.

576 While the *Rod*$^{\Delta Vhl}$ model has chronically active HIFs in normoxic rods causing HIF1-dependent
577 photoreceptor degeneration [8], the RPE-specific deletion of *Vegfa* in the *RPE*$^{\Delta Vegfa}$ model affects
578 the choroidal vasculature, causing true tissue hypoxia and leading to HIF2-dependent RPE
579 damage and to retinal degeneration [7]. Since the true tissue hypoxia in *RPE*$^{\Delta Vegfa}$ mice affects
580 multiple cell types and elicits broad effects including changes in metabolism [7], *RPE*$^{\Delta Vegfa}$ mice
581 may represent the complex, multifactorial environment in the aging eye with some accuracy.
582 To knockdown *Vegfa* in adult RPE cells, we delivered a VMD2-controlled Cre transgene to
583 *Vegfa*$^{fl/fl}$ mice. This approach is more specific, efficient and reproducible compared to methods
584 suffering from variable and patchy Cre expression in RPE of transgenic mice [41,53] or the lack
585 of cell type specificity after delivery of CjCas9 for indel generation [40].

586 The therapeutic vector was designed to express shHif1 in photoreceptors and shHif2 in the
587 RPE with GFP and mCherry as surrogate markers. Despite that the expression of GFP::shHif1
588 was controlled by the GRK1 promotor, GFP fluorescence was also visible in the RPE (Fig.
589 3D,E). This was likely due to phagocytosis of photoreceptor material by the RPE, or to some
590 expression of the gene in the RPE following delivery by AAV8, which has a known tropism for
591 the RPE, as observed in macaque studies [38]. This opens the possibility that some molecules
592 targeting *Hif1a* mRNA reached the RPE. Although phagocytosed material would likely be
593 confined to lysosomes, we cannot exclude some downregulation of *Hif1a* transcripts in the
594 RPE by such 'spills'. However, since the knockout of *Hif1a* in the mouse RPE does not cause
595 phenotypic changes [41] this possibility does not significantly influence the validity, specificity
596 and efficacy of our approach.

597 Although our dual-active RNA therapy rescued the phenotype in both mouse models, our
598 results suggest a higher efficiency in *RPE*$^{\Delta Vegfa}$ mice where degeneration is based on true
599 hypoxia due to pathological changes in the choroidal vasculature (Fig. 4C). The RNA-induced
600 silencing complex (RISC) that is formed after shRNA expression reduces stability or translation
601 of mRNA transcripts but does not affect preformed proteins. Thus, the efficacy of shRNA-

602 mediated downregulation of protein activity depends on the expression levels of the target
603 RNA. Considering reports suggesting that hypoxia can reduce levels and half-lives of *Hif1a*
604 and *Hif2a* transcripts [54,55], it appears possible that RNA interference is more effective in the
605 model of true hypoxia due to lower levels of target mRNAs. Clearly, unraveling the mechanisms
606 that contribute to the differences in treatment efficacies in the two models needs further
607 research and is important to further improve the RNA interference approach. A limitation of our
608 study lies in structural differences between the mouse and the human retina. Unlike humans,
609 mice do not possess a macula which prevents our models from presenting all aspects of AMD.
610 However, since the molecular response to hypoxia with the activation of HIF transcription
611 factors is quite universal, we nonetheless believe that our RNA therapy targeting this
612 conserved mechanism is translatable in the future to the human situation.

613

614 Conclusion

615 Since a reduction of oxygen delivery to the outer retina through the choroidal system affects
616 both RPE and photoreceptors, it is important that a therapeutic intervention targets the
617 degeneration-causing factors in both cell types simultaneously and specifically. We
618 approached these requirements through the dual-active multiplex RNAi therapy system using
619 a single AAV. Delivery of therapeutic genes by AAV is safe and has been evaluated in several
620 clinical trials [56,57]. The first FDA and EMA-approved gene therapy (Luxturna©) for Leber
621 congenital amaurosis type 2 not only supports the safety but also the efficacy of the delivery
622 of genetic material to target cells by subretinal AAV injections. The approach presented here
623 further expands the potential of AAVs as a therapeutic system by using a single AAV vector
624 with two specific Pol-II promotors to drive expression of shRNAs targeting two transcripts in
625 two distinct cell types. We believe that the system demonstrates potential for widespread
626 applicability to other multifactorial diseases that necessitate modifications of gene expression
627 across various cell types or tissues. Since RNAi-based therapeutics, including siRNA and

628 shRNA, have already been used in several clinical trials, e.g., to target cancer or genetic
629 disorders [58,59], the system developed here has the potential to be translated for the use in
630 patients, particularly for the treatment of retinal disorders associated with a chronic hypoxic
631 response such as AMD.
632

633 ## List of abbreviations

634 AAV: adeno-associated virus
635 AMD: age-related macular degeneration
636 ARR3: cone arrestin
637 BM: Bruch's membrane
638 CC: choriocapillaris
639 CTNB1: beta-catenin
640 Ctrl: control
641 DAPI: 4',6-diamidino-2-phenylindole
642 ERG: electroretinogram
643 Fl: flox
644 GCL: ganglion cell layer
645 GFP: green fluorescent protein
646 GRK1: G-protein coupled kinase 1
647 HIF: hypoxia-inducible factor
648 IBA1: allograft inflammatory factor 1
649 INL: inner nuclear layer
650 miR: microRNA
651 OCT: optical coherence tomography
652 ONL: outer nuclear layer
653 PFA: paraformaldehyde
654 PODXL: podocalyxin
655 PS: photoreceptor segment
656 VEGFA: vascular endothelial growth factor A
657 RPE: retinal pigment epithelium
658 siRNA: small interfering RNA

shRNA: small hairpin RNA
VHL: von Hippel Lindau
VMD2: vitelliform macular dystrophy 2
WPI: weeks post injection
WT: wild type
3'UTR: 3' untranslated region

Declarations

Ethics approval and consent to participate

Analysis of human ocular tissue was approved by the Cantonal Ethic Commission (license numbers BASEC-Nr: PB_2017-00550 and 2020-01856) and adhered to the tenets of the Declaration of Helsinki. Animal experimentation was approved by the Cantonal Veterinary Office of Zürich, Switzerland (license numbers: ZH019/2019 and ZH105/2022) and adhered to the ARVO statement for the use of Animals in Ophthalmic and Vision Research.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this article and its supplementary information files.

Competing interest

The authors declare that they have no competing interests.

Funding

This work was supported by Swiss National Science Foundation grants 31003A_173008 and 310030_200798, and a research grant of the University of Zürich to L.E. (FK-20-028).

Authors' contributions

L.E. M.S. and C.G. conceived the study. L.E. designed and performed experiments and the analysis. I.M and F.B. collected human ocular tissue. M.S.; C.I.; D.K.; F.P; E.K.; A.F.; D.F.; L.M.; G.W.; I.T., L.G., SL.B.; SE.B. contributed to data collection and performed experiments. All authors contributed to project design, organization of the experiments, interpretation of results. L.E., M.S. and C.G wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The Viral Vector Facility (VVF) of the Neuroscience Center Zurich (ZNZ) produced all AAVs and the Laboratory Animal Services Center (LASC) of the University of Zurich was responsible for animal care.

Figure legends

Figure 1 | Gene expression in the human retina and RPE. Expression of *VEGFA, ANGPTL4, SERPINE1, GNAT2,* and *RPE65* was determined by real-time PCR in the retina **(A)** and RPE **(B)** of young (Y) and old (O) human donor eyes without diagnosed ocular pathology. Shown are means (line) and individual data points on a log10 scale. Outliers were identified and excluded using Grubbs method, and significance was determined by unpaired t-tests. N = 15 (young) and 14 (old).

710 **Figure 2 | *In vitro* validation of *Hif1a* and *Hif2a* shRNAs and design of the dual-acting**
711 **AAV vector. (A)** Graphical representation of tissue changes leading to hypoxia and
712 degenerative processes during aging and AMD. **(B)** Gene expression analysis of 661W cells
713 stably expressing shCtrl, shHif1 or shHif2 after normoxic or hypoxic (24 h, 0.2% O_2) exposure.
714 Values were normalized to beta-actin (*Actb*) and expressed relatively to normoxic 661W-shCtrl
715 (set to 1). Shown are individual values (n=3) and means ± SD. Significance was tested using
716 a one-way ANOVA with Tukey's multiple comparison test. *: statistically significant; p-values
717 of all comparisons are given in Table S2. **(C)** Western blot analysis for HIF1A, HIF2A and
718 ACTB in 661W cells stably expressing shCtrl, shHif1 or shHif2 after normoxic and hypoxic
719 exposure. The position of the band for HIF1A is indicated by an arrow. **(D)** Schematic
720 representation of the DNA constructs packaged into AAV vectors. AAV-shHif: the construct
721 consists of the GRK1 promotor driving photoreceptor-specific expression of shHif1a embedded
722 in the miR-E scaffold in the 3'UTR of GFP, followed by the VMD2 promotor controlling RPE-
723 specific expression of shHif2a embedded in the miR-E scaffold in the 3'UTR of mCherry. AAV-
724 shCtrl: a scrambled non-targeting control shRNA sequence replaced shHif1a and shHif2a.
725 AAV-shHif1: the GRK1 promotor drives photoreceptor-specific expression of shHif1a
726 embedded in the miR-E scaffold in the 3'UTR of GFP. AAV-shHif2: the VMD2 promotor
727 controls expression of shHif2a embedded in the miR-E scaffold in the 3'UTR of mCherry in the
728 RPE. Sequences of shRNAs are provided in Fig. S1 and supplemental data SD1. CC:
729 choriocapillaris, BM: Bruch`s membrane, RPE: retinal pigment epithelium, PS: photoreceptor
730 segments, ONL: outer nuclear layer.
731

732 **Figure 3 | Evaluation of the pattern and tolerability of shHif expression in wt mice after**
733 **AAV-mediated delivery. (A)** Illustration of transvitreal AAV-delivery to the subretinal space
734 targeting photoreceptor cells (shown in green due to expression of GFP) and RPE cells (shown
735 in red due to expression of mCherry). **(B, C)** Funduscopy, OCT scans and fundus fluorescence
736 of wt mice injected with shCtrl (B) or shHif (C) at 2 wpi. Orange and red lines in the fundus

737 images indicate positions of the respective OCT scans. Fluorescence indicates transduced
738 areas in the retina (green, GFP) and RPE (red, mCherry). White arrows: injection site, *: optic
739 nerve head. **(D, E)** Retinal cross-sections of wt mice injected with shCtrl (D) or shHif (E) at 3
740 wpi. Green/white: GFP-positive photoreceptors / RPE. Red/white: mCherry-positive RPE cells.
741 Shown are merged images (left) and individual fluorescence channels (middle and right). **(F,**
742 **G)** Retina and their corresponding RPE flatmounts from wt mice injected with shCtrl (F) or
743 shHif (G) at 3 wpi. Shown are native GFP (green) and mCherry (red) fluorescence and
744 stainings for IBA1 (white). Boxed areas in the fluorescence images are shown in higher
745 magnification (middle). Arrow: injection site. **(H)** Representative retinal morphologies of wt
746 mice injected with shCtrl (left) or shHif (right) at 22 wpi. **(I)** Scotopic and photopic
747 electroretinograms (ERG) of wt mice injected with shCtrl (grey) or shHif (orange) at 22 wpi.
748 Shown are scotopic a- and b-wave and photopic b-wave amplitudes as a function of stimulus
749 intensity. Shaded areas indicate SD, n=4 per group. Scale bars: as indicated. BM: Bruch's
750 membrane, RPE: retinal pigment epithelium, PS: photoreceptor segments, ONL: outer nuclear
751 layer, INL: inner nuclear layer, GCL: ganglion cell layer, SRS: subretinal space.

752

753 **Figure 4 | Assessment of the *RPE*$^{\Delta Vegfa}$ phenotype. (A)** *RPE*$^{\Delta Vegfa}$ model schematics: *Vegfa*
754 deletion in the RPE leads to reduced choroidal vessel density, RPE alterations and
755 photoreceptor degeneration. **(B)** *Vegfa* (red) *in situ* hybridization and Cre (magenta)
756 immunofluorescence in areas that were or were not transduced with AAV::VMD2-Cre-P2A-
757 eGFP. **(C)** PODXL immunofluorescence in endothelial cells of choroidal flatmounts (top) and
758 cross-sections (lower panels) of indicated areas. Contrast-enhanced threshold images allowed
759 pixel intensity scan analysis (bottom) and quantification (right) in *RPE*$^{\Delta Vegfa}$ mice at 3 wpi. Data
760 from n=3 eyes, 18-19 measurements/area, analyzed by unpaired t-test. **(D)** Funduscopy, OCT
761 scans, fundus fluorescence and angiography of *RPE*$^{\Delta Vegfa}$ mice at 3 (top) and 39 (bottom) wpi.
762 Fundus images with orange/red lines indicate OCT scan positions. GFP-labelled panels show
763 green fluorescence confirming the presence of Cre at 3 wpi; background fluorescence

764 dominates at 39 wpi. Arrows: injection site, *: optic nerve head. **(E)** Representative color-coded
765 ONL thickness maps generated from OCT volume scans at 39 wpi. Right panel: boxplots of
766 ONL thickness in the two nasal subfields in mice. Shown are average values of individual eyes
767 (dots) and means of all eyes (line). Note: values for control injected mice (*Vegfa*$^{fl/fl}$ + PBS and
768 *Vegfa*$^{fl/fl}$ + GFP) were combined. n=4 (*Vegfa*$^{fl/fl}$); n=11 (*RPE*$^{\Delta Vegfa}$); n=6 (*Vegfa*$^{fl/fl}$ + GFP /
769 *Vegfa*$^{fl/fl}$ + PBS). One-way ANOVA with Tukey's multiple comparison test. P-values as shown.
770 **(F)** Representative retinal histology of *Vegfa*$^{fl/fl}$ mice (left) subretinally injected with AAVs
771 expressing Cre (*RPE*$^{\Delta Vegfa}$) or GFP (*Vegfa*$^{fl/fl}$ + GFP), or with PBS (*Vegfa*$^{fl/fl}$ + PBS) at 39 wpi.
772 **(G)** ONL thickness and PS length quantified from histological sections 39 wpi. Shown are
773 spidergrams and average values in the transduced nasal area (boxplots, 400-2000 µm from
774 the optic nerve head (ON)) of indicated groups at 39 wpi. Shown are means ± SD and individual
775 data points. n=3 (*Vegfa*$^{fl/fl}$; *Vegfa*$^{fl/fl}$ + GFP; *Vegfa*$^{fl/fl}$ + PBS); n=2 (*RPE*$^{\Delta Vegfa}$). One-way ANOVA
776 with Tukey's multiple comparison test, p-values as indicated. CC: choriocapillaris, BM: Bruch's
777 membrane, RPE: retinal pigment epithelium, PS: photoreceptor segments, ONL: outer nuclear
778 layer, INL: inner nuclear layer, GCL: ganglion cell layer. DIC: differential interference contrast.

779

780 **Figure 5 | Rescue of the *Rod*$^{\Delta Vhl}$ phenotype by the dual-acting shHif RNA therapy. (A)**
781 Schematic representation of *Rod*$^{\Delta Vhl}$ mice and rescue of RPE (red) and photoreceptors (green)
782 through downregulation of *Hif2a* in the RPE and *Hif1a* in photoreceptors and *Hif2a* in the RPE
783 by shHif. **(B)** Funduscopy, OCT scans and fundus fluorescence assessed at 26 weeks of age
784 (22 wpi) in *Rod*$^{\Delta Vhl}$ mice that were either non-injected (left) or treated with shCtrl (middle) or
785 shHif (right). Orange and red lines in the fundus images indicate positions of the respective
786 OCT scans. OCT scans of higher magnifications are included. Fundus fluorescence images
787 (last two rows) show the transduced areas in the retina (green, GFP) and RPE (red, mCherry).
788 *: optic nerve head. **(C)** Color-coded ONL thickness maps of *Vhl*$^{fl/fl}$, *Rod*$^{\Delta Vhl}$ + shCtrl and *Rod*$^{\Delta Vhl}$
789 + shHif mice generated from OCT volume scans at 22 wpi. Grids were aligned to the optic
790 nerve (ON). The ONL thickness was measured in seven subfields and indicated with numbers

791 (artificial units). Right panel: quantification of ONL thickness in the seven subfields (outlined
792 by the orange line in the grid). Shown are average values of the subfields in individual eyes
793 (dots) and means of all eyes (line) in box blots (n≥9). One-way ANOVA with Tukey's multiple
794 comparison test. P-values as shown. **(D)** Representative retinal morphologies of transduced
795 regions of *Vhl*$^{fl/fl}$ control and *Rod*$^{\Delta Vhl}$ mice injected with shCtrl or shHif. All mice were 26 weeks
796 of age (22 wpi) at time of analysis. **(E, F)** Relative gene expression levels in retinas (E) or
797 eyecups (F) of *Rod*$^{\Delta Vhl}$ + shCtrl (grey) and *Rod*$^{\Delta Vhl}$ + shHif (orange) mice at 22 wpi. Expression
798 was normalized to beta-actin (*Actb*) and shown relative to expression in *Rod*$^{\Delta Vhl}$ + shCtrl mice
799 (set to 1). Shown are means ± SD of n = 11-12. Unpaired t-test. P-values as indicated. RPE:
800 retinal pigment epithelium, ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion
801 cell layer.

802

803 **Figure 6 | Dual-acting multiplex shRNA therapy is more effective than single acting**
804 **shRNA vectors in rescuing pathology in *RPE*$^{\Delta Vegfa}$ mice.**
805 **(A)** Funduscopy, OCT scans and fundus fluorescence of *RPE*$^{\Delta Vegfa}$ mice injected with shCtrl
806 (left) or shHif (right) at 39 wpi. Orange and red lines in the fundus images indicate positions of
807 the respective OCT scans that are shown in lower and higher magnifications. Fundus
808 fluorescence indicates transduced areas in the retina (green, GFP) and RPE (red, mCherry).
809 *: optic nerve head. **(B)** Color-coded ONL thickness maps generated from OCT volume scans
810 of *RPE*$^{\Delta Vegfa}$ + shCtrl, *RPE*$^{\Delta Vegfa}$ + shHif, *RPE*$^{\Delta Vegfa}$ + shHif1 and *RPE*$^{\Delta Vegfa}$ + shHif2 mice at 39
811 wpi. Grids were aligned to the optic nerve (ON). The ONL thickness was measured in the two
812 nasal subfields (outlined by the orange line in the grid) that were most affected in *RPE*$^{\Delta Vegfa}$
813 mice and indicated with numbers (artificial units). Right panel: quantification of ONL thickness
814 in the nasal two subfields. Shown are average values in individual eyes (dots) and means of
815 all eyes (line) in box blots. n=11 (shCtrl, shHif); n=9 (shHif1); n=8 (shHif2). One-way ANOVA
816 with Dunnett's multiple comparison test comparing all groups to shHif. p-values as shown. **(C)**
817 Representative retinal morphologies of transduced and non-transduced areas in *RPE*$^{\Delta Vegfa}$

818 mice treated with AAVs as indicated. Analysis was at 39 wpi. **(D)** Quantification of ONL
819 thickness and PS length of the four treatment groups. Shown are spidergrams and average
820 values of the transduced nasal area (400-2000 µm from the optic nerve head (ON)) of a subset
821 of mice that were already analyzed by volume scans (B) at 39 wpi. Grey: shCtrl; orange: shHif;
822 green shHif1; blue: shHif2. Shown are means ± SD and individual data points. One-way
823 ANOVA with Dunnett's multiple comparison test comparing all groups to shHif. P-values as
824 shown. shHif: n=4 (ONL) and n=3 (PS); shHif1: n=9 (ONL) and n=4 (PS); shHif2: n=8 (ONL)
825 and n=6 (PS); shCtrl: n=2 (ONL and PS). RPE: retinal pigment epithelium, PS: photoreceptor
826 segments, ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell layer, BM:
827 Bruch's membrane.
828
829 **Figure 7 | Long-lasting rescue of the *RPE*$^{\Delta Vegfa}$ phenotype by the dual-acting shRNA**
830 **therapy**
831 **(A, B)** Funduscopy and fundus fluorescence of *RPE*$^{\Delta Vegfa}$ mice injected with shCtrl (top) or
832 shHif (bottom) analyzed at 4 wpi (A) and 61 wpi (B). Fluorescence indicates transduced areas
833 in the retina (green, GFP) and RPE (red, mCherry). *: optic nerve head. **(C)** Representative
834 retinal morphologies of transduced and non-transduced areas of *RPE*$^{\Delta Vegfa}$ mice injected with
835 shCtrl or shHif, analyzed at 61 wpi. **(D)** Quantification of ONL thickness and PS length at 61
836 wpi, presented as spidergrams (left) and boxplots (right) presenting the averaged values of the
837 transduced nasal area (400-2000 µm from the optic nerve head (ON)). Treatment groups:
838 *Vegfa*$^{flox/flox}$ mice injected with GFP control virus (green), *RPE*$^{\Delta Vegfa}$ + shHif mice (orange) and
839 *RPE*$^{\Delta Vegfa}$ + shCtrl mice (grey) at 61 wpi. Note: ONL thickness and PS length in *Vegfa*$^{flox/flox}$ +
840 GFP mice are not shown in spidergrams to reduce complexity of the figure panels. Shown are
841 means ± SD and individual data points. One-way ANOVA with Tukey's multiple comparison
842 tests. P-values as shown. shHif: n=11 (ONL) and n= 9 (PS); shCtrl: n=10 (ONL) and n=6 (PS);
843 GFP: n=3 (ONL and PS).
844

845 **References**

846 1. Zhu, Y., Zhu, L., Wang, X. & Jin, H. RNA-based therapeutics: an overview and prospectus. *Cell*
847 *Death Dis* **13**, 644 (2022).

848 2. Grunwald, J. E., Metelitsina, T. I., Dupont, J. C., Ying, G. S. & Maguire, M. G. Reduced foveolar
849 choroidal blood flow in eyes with increasing AMD severity. *Invest Ophthalmol Vis Sci* **46**, 1033–
850 1038 (2005).

851 3. Berenberg, T. L. *et al.* The association between drusen extent and foveolar choroidal blood flow
852 in age-related macular degeneration. *Retina* **32**, 25–31 (2012).

853 4. Ramrattan, R. S. *et al.* Morphometric analysis of Bruch's membrane, the choriocapillaris, and the
854 choroid in aging. *Invest Ophthalmol Vis Sci* **35**, 2857–2864 (1994).

855 5. Wakatsuki, Y., Shinojima, A., Kawamura, A. & Yuzawa, M. Correlation of Aging and Segmental
856 Choroidal Thickness Measurement using Swept Source Optical Coherence Tomography in
857 Healthy Eyes. *PLoS One* **10**, e0144156 (2015).

858 6. Mullins, R. F., Johnson, M. N., Faidley, E. A., Skeie, J. M. & Huang, J. Choriocapillaris vascular
859 dropout related to density of drusen in human eyes with early age-related macular degeneration.
860 *Invest Ophthalmol Vis Sci* **52**, 1606–1612 (2011).

861 7. Kurihara, T. *et al.* Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient
862 to induce photoreceptor degeneration. *Elife* **5**, (2016).

863 8. Barben, M. *et al.* Hif1a inactivation rescues photoreceptor degeneration induced by a chronic
864 hypoxia-like stress. *Cell Death Differ* **25**, 2071–2085 (2018).

865 9. Lange, C. *et al.* Retina-specific activation of a sustained hypoxia-like response leads to severe
866 retinal degeneration and loss of vision. *Neurobiol Dis* **41**, 119–130 (2011).

867 10. Khan, A. A. *et al.* Transfection of small RNAs globally perturbs gene regulation by endogenous
868 microRNAs. *Nat Biotechnol* **27**, 549–555 (2009).

869 11. Martin, J. N. *et al.* Lethal toxicity caused by expression of shRNA in the mouse striatum:
870 implications for therapeutic design. *Gene Ther* **18**, 666–673 (2011).

871 12. Snøve, O. & Rossi, J. J. Toxicity in mice expressing short hairpin RNAs gives new insight into
872 RNAi. *Genome Biol* **7**, 231 (2006).

873 13. Lee, Y. *et al.* The nuclear RNase III Drosha initiates microRNA processing. *Nature* **425**, 415–419
874 (2003).

875 14. Silva, J. M. *et al.* Second-generation shRNA libraries covering the mouse and human genomes.
876 *Nat Genet* **37**, 1281–1288 (2005).

877 15. Bauer, M. *et al.* Prevention of interferon-stimulated gene expression using microRNA-designed
878 hairpins. *Gene Ther* **16**, 142–147 (2009).

879 16. Gu, S. *et al.* The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer
880 processing in vivo. *Cell* **151**, 900–911 (2012).

881 17. Fellmann, C. *et al.* An optimized microRNA backbone for effective single-copy RNAi. *Cell Rep* **5**,
882 1704–1713 (2013).

883 18. Haase, V. H., Glickman, J. N., Socolovsky, M. & Jaenisch, R. Vascular tumors in livers with
884 targeted inactivation of the von Hippel-Lindau tumor suppressor. *Proc Natl Acad Sci U S A* **98**,
885 1583–1588 (2001).

886 19. Le, Y. Z. *et al.* Mouse opsin promoter-directed Cre recombinase expression in transgenic mice.
887 *Mol Vis* **12**, 389–398 (2006).

888 20. Gerber, H. P. *et al.* VEGF is required for growth and survival in neonatal mice. *Development* **126**,
889 1149–1159 (1999).

890 21. Kay, C. N. *et al.* Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated
891 AAV vectors. *PLoS One* **8**, e62097 (2013).

892 22. Storti, F. *et al.* Impaired ABCA1/ABCG1-mediated lipid efflux in the mouse retinal pigment
893 epithelium (RPE) leads to retinal degeneration. *Elife* **8**, (2019).

894 23. Gasparini, S. J. *et al.* Transplanted human cones incorporate into the retina and function in a
895 murine cone degeneration model. *J Clin Invest* **132**, (2022).

896 24. Geiger, P., Barben, M., Grimm, C. & Samardzija, M. Blue light-induced retinal lesions, intraretinal
897 vascular leakage and edema formation in the all-cone mouse retina. *Cell Death Dis* **6**, e1985
898 (2015).

899 25. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time
900 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**, 402–408 (2001).

901 26. Ebner, L. J. A. *et al.* Transcriptomic analysis of the mouse retina after acute and chronic
902 normobaric and hypobaric hypoxia. *Sci Rep* **11**, 16666 (2021).

903 27. Tan, E. *et al.* Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal
904 tumors in transgenic mice. *Invest Ophthalmol Vis Sci* **45**, 764–768 (2004).

905 28. Meade, E. S., Ma, Y. Y. & Guller, S. Role of hypoxia-inducible transcription factors 1alpha and
906 2alpha in the regulation of plasminogen activator inhibitor-1 expression in a human trophoblast
907 cell line. *Placenta* **28**, 1012–1019 (2007).

908 29. Qin, Y. *et al.* ANGPTL4 influences the therapeutic response of patients with neovascular age-
909 related macular degeneration by promoting choroidal neovascularization. *JCI Insight* **7**, (2022).

910 30. Semenza, G. L. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* **3**, 721–732 (2003).

911 31. Biasella, F. *et al.* Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to Vascular
912 Changes in AMD Pathobiology. *Cells* **11**, (2022).

913 32. Witmer, A. N., Vrensen, G. F., Van Noorden, C. J. & Schlingemann, R. O. Vascular endothelial
914 growth factors and angiogenesis in eye disease. *Prog Retin Eye Res* **22**, 1–29 (2003).

915 33. Ronning, K. E. *et al.* Loss of cone function without degeneration in a novel Gnat2 knock-out
916 mouse. *Exp Eye Res* **171**, 111–118 (2018).

917 34. Redmond, T. M. *et al.* Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual
918 cycle. *Nat Genet* **20**, 344–351 (1998).

919 35. Chhipa, R. R. *et al.* AMP kinase promotes glioblastoma bioenergetics and tumour growth. *Nat*
920 *Cell Biol* **20**, 823–835 (2018).

921 36. Khani, S. C. *et al.* AAV-mediated expression targeting of rod and cone photoreceptors with a
922 human rhodopsin kinase promoter. *Invest Ophthalmol Vis Sci* **48**, 3954–3961 (2007).

923 37. Esumi, N., Oshima, Y., Li, Y., Campochiaro, P. A. & Zack, D. J. Analysis of the VMD2 promoter
924 and implication of E-box binding factors in its regulation. *J Biol Chem* **279**, 19064–19073 (2004).

925 38. Crosson, S. M. *et al.* Effects of Altering HSPG Binding and Capsid Hydrophilicity on Retinal
926 Transduction by AAV. *J Virol* **95**, (2021).

927 39. Nsiah, N. Y., Morgan, A. B., Donkor, N. & Inman, D. M. Long-term HIF-1α stabilization reduces
928 respiration, promotes mitophagy, and results in retinal cell death. *Sci Rep* **13**, 20541 (2023).

929 40. Kim, E. *et al.* In vivo genome editing with a small Cas9 orthologue derived from Campylobacter
930 jejuni. *Nat Commun* **8**, 14500 (2017).

931 41. Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E. & Friedlander, M. Targeted deletion of
932 Vegfa in adult mice induces vision loss. *J Clin Invest* **122**, 4213–4217 (2012).

933 42. Eren, M., Boe, A. E., Klyachko, E. A. & Vaughan, D. E. Role of plasminogen activator inhibitor-1
934 in senescence and aging. *Semin Thromb Hemost* **40**, 645–651 (2014).

935 43. Nolan, N. D. *et al.* CRISPR editing of anti-anemia drug target rescues independent preclinical
936 models of retinitis pigmentosa. *Cell Rep Med* **5**, 101459 (2024).

937 44. Todorova, V. *et al.* Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor
938 degeneration during chronic HIF activation. *Mol Neurodegener* **18**, 15 (2023).

939 45. McHugh, K. J. *et al.* Computational modeling of retinal hypoxia and photoreceptor degeneration
940 in patients with age-related macular degeneration. *PLoS One* **14**, e0216215 (2019).

941 46. Stefánsson, E., Geirsdóttir, A. & Sigurdsson, H. Metabolic physiology in age related macular
942 degeneration. *Prog Retin Eye Res* **30**, 72–80 (2011).

943 47. Grimm, D. *et al.* Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA
944 pathways. *Nature* **441**, 537–541 (2006).

945 48. Babapoor-Farrokhran, S. *et al.* Pathologic vs. protective roles of hypoxia-inducible factor 1 in RPE
946 and photoreceptors in wet vs. dry age-related macular degeneration. *Proc Natl Acad Sci U S A*
947 **120**, e2302845120 (2023).

948 49. Landfried, B. *et al.* Digoxin-induced retinal degeneration depends on rhodopsin. *Cell Death Dis* **8**,
949 e2670 (2017).

950 50. Chen, R., Ahmed, M. A. & Forsyth, N. R. Dimethyloxalylglycine (DMOG), a Hypoxia Mimetic
951 Agent, Does Not Replicate a Rat Pheochromocytoma (PC12) Cell Biological Response to
952 Reduced Oxygen Culture. *Biomolecules* **12**, (2022).

953 51. Zhdanov, A. V., Okkelman, I. A., Collins, F. W., Melgar, S. & Papkovsky, D. B. A novel effect of
954 DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene
955 expression. *Biochim Biophys Acta* **1847**, 1254–1266 (2015).

956 52. Grimm, C. *et al.* HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced
957 retinal degeneration. *Nat Med* **8**, 718–724 (2002).

958 53. Le, Y. Z. *et al.* Inducible expression of cre recombinase in the retinal pigmented epithelium. *Invest*
959 *Ophthalmol Vis Sci* **49**, 1248–1253 (2008).

960 54. Bartoszewski, R. *et al.* Primary endothelial cell-specific regulation of hypoxia-inducible factor
961 (HIF)-1 and HIF-2 and their target gene expression profiles during hypoxia. *FASEB J* **33**, 7929–
962 7941 (2019).

963 55. Chamboredon, S. *et al.* Hypoxia-inducible factor-1α mRNA: a new target for destabilization by
964 tristetraprolin in endothelial cells. *Mol Biol Cell* **22**, 3366–3378 (2011).

965 56. Balakrishnan, B. & Jayandharan, G. R. Basic biology of adeno-associated virus (AAV) vectors
966 used in gene therapy. *Curr Gene Ther* **14**, 86–100 (2014).

967 57. Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful
968 gene therapy. *Blood* **122**, 23–36 (2013).

969 58. Burnett, J. C., Rossi, J. J. & Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical
970 trials. *Biotechnol J* **6**, 1130–1146 (2011).

971 59. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA
972 delivery. *Nat Rev Drug Discov* **8**, 129–138 (2009).

973

974 ## Supplementary Figures

975 **Figure S1 | Schematic representation of shRNAmir constructs with the miR-E backbone**
976 **and shHif1a, shHif2a and shCtrl target sequences.**
977 **(A-C)** Sequences of the shRNAmir constructs. Restriction enzymes used for cloning, the 5'
978 complement, the basal stem, the target sequence, and the 3' flank are indicated.
979

980 **Figure S2 | Evaluation of shHif2_1-6 in 661W cells**
981 *Hif2a* mRNA levels in 661W cell lines stably expressing shCtrl or shHif2_1-6. Expression was
982 normalized to beta-actin (*Actb*) and shown relative to expression of shCtrl (set to 1). Shown
983 are means and individual values, n=2.

984

985 **Figure S3 | Assessment of AAV-shHif injection in wt mice**
986 *In situ* hybridization of retinal cross-sections from wt mice at 3 wpi detecting **(A)** *Hif1a* RNA in
987 the shHif-transduced and the non-transduced retina or **(B)** *Hif2a* in the RPE transduced either
988 with shHif or shCtrl AAVs. Shown are *in situ* fluorescence (red) and bright-field images (grey).
989 **(C)** GFP fluorescence and immunostainings in retinal cross-sections of wt mice injected with
990 PBS, shCtrl, or shHif at 3 wpi. Green: GFP; magenta/white: IBA1; grey: DAPI (nuclear stain).
991 Shown are merged images (left) and single-channel images for IBA1 (right). RPE: retinal
992 pigment epithelium. ONL: outer nuclear layer. INL: inner nuclear layer. GCL: ganglion cell
993 layer. **(D)** Representative flatmount images of retina (top) and corresponding RPE (bottom) of
994 wt mice injected with shCtrl (left) or shHif (right) at 3 wpi. GFP and mCherry fluorescence
995 indicate the transduced area. Arrow: injection site. Antibodies for cone arrestin (ARR3, white)
996 and beta-catenin (CTNB1, white) were used to stain cone photoreceptors and RPE cells,
997 respectively. **(E)** Light microscopic images of panorama sections through retinas of wt mice
998 injected with shCtrl (left) or shHif (right) at 22 wpi. Scale bar as indicated.

999

1000 **Figure S4 | Phenotype of *RPE*$^{\Delta Vegfa}$ mice.**

1001 Light microscopic panorama image of a retina section from an *RPE*$^{\Delta Vegfa}$ mouse (injected with
1002 $1x10^9$ vg/µL AAV::VMD2-Cre-P2A-eGFP) at 39 wpi. The area transduced with the virus
1003 resulting in an RPE-specific *Vegfa* knockout is marked. Insets: higher magnifications of boxed
1004 areas. RPE: retinal pigment epithelium. PS: photoreceptor segments. ONL: outer nuclear
1005 layer. INL: inner nuclear layer. GCL: ganglion cell layer. Scale bar as indicated.

1006

1007 **Supplemental data file 1 | AAV-plasmid sequences for shHif and shCtrl.**

1008 The shHif1, shHif2, and shCtrl sequences are highlighted in red, green, and blue, respectively.

Table 1 | Primer sequences for real-time PCR

Gene	Forward primer (5'-3')	Reverse Primer (5'-3')
	Mouse genes	
Actb	CAACGGCTCCGGCATGTGC	CTCTTGCTCTGGGCCTCG
Hif1a	CAATGTCTCCTTTACCTTCATCGG	TGGATTCTTTGCCTCTGTGTCTTC
Hif2a	GGAGCTCAAAAGGTGTCAGG	CAGGTAAGGCTCGAACGATG
Slc2a1	AGTGTATCCTGTTGCCCTTCTG	GCCGACCCTCTTCTTTCATCTC
Casp1	GGCAGGAATTCTGGAGCTTCAA	GTCAGTCCTGGAAATGTGCC
Pde6b	TCTGGAGGATTGCCTGGTG	GGCGAATGAGCTGAAGTGG
Rpe65	AAAGCAGACAAGGAAGATCCAA	CCCAAAGACTCCACGAAGAA
	Human genes	
ACTB	CCTGGCACCCAGCACAAT	GGGCCGGACTCGTCATAC
VEGFA	GTGGACATCTTCCAGGAGTACC	TGTTGTGCTGTAGGAAGCTCAT
ANGPTL4	AGAGGCAGAGTGGACTATTTG	TGGCGCCTCTGAATTACTG
SERPINE1	ACAAATCAGACGGCAGCAC	TAGGGCAGTTCCAGGATGTC
RPE65	TTGTGGATCTCTGCTGCTGGAA	GGAGCGTGACTAAATTCTTGCCT
GNAT2	CTGCTACTGCTGGGTGCT	TGGTGAATAGCCATCCTGGT

Table 2 | Treatment groups and AAVs

Treatment group	Mouse strain	Capsid	DNA construct
		Single AAV injections	
WT + shCtrl	B6/J-Crl1	AAV8-TM	GRK1-GFP-shCtrl-VMD2-mCherry-shCtrl
WT + shHif	B6/J-Crl1	AAV8-TM	GRK1-GFP-shHif1-VMD2-mCherry-shHif2
Rod$^{\Delta Vhl}$ + shCtrl	*Vhl$^{fl/fl}$;Opsin-Cre*	AAV8-TM	GRK1-GFP-shCtrl-VMD2-mCherry-shCtrl
Rod$^{\Delta Vhl}$ + shHif	*Vhl$^{fl/fl}$;Opsin-Cre*	AAV8-TM	GRK1-GFP-shHif1-VMD2-mCherry-shHif2
Vegfa$^{fl/fl}$ + GFP	*Vegfa$^{fl/fl}$*	AAV4	VMD2-eGFP
RPE$^{\Delta Vegfa}$	*Vegfa$^{fl/fl}$*	AAV4	VMD2-Cre-P2A-eGFP
		Double AAV injections (combined with AAV4/2::VMD2-Cre-P2A-GFP)	
RPE$^{\Delta Vegfa}$ + shCtrl	*Vegfa$^{fl/fl}$*	AAV8-TM	GRK1-GFP-shCtrl-VMD2-mCherry-shCtrl
RPE$^{\Delta Vegfa}$ + shHif	*Vegfa$^{fl/fl}$*	AAV8-TM	GRK1-GFP-shHif1-VMD2-mCherry-shHif2
RPE$^{\Delta Vegfa}$ + shHif1	*Vegfa$^{fl/fl}$*	AAV8-TM	GRK1-GFP-shHif1
RPE$^{\Delta Vegfa}$ + shHif2	*Vegfa$^{fl/fl}$*	AAV8-TM	VMD2-mCherry-shHif2
		PBS and uninjected	
Vhl$^{fl/fl}$	*Vhl$^{fl/fl}$*	n.a.	n.a.
Vegfa$^{fl/fl}$	*Vegfa$^{fl/fl}$*	n.a.	n.a.
Vegfa$^{fl/fl}$ + PBS	*Vegfa$^{fl/fl}$*	n.a.	n.a. (PBS)

All AAVs have type 2 ITRs. AAV8-TM: AAV8-tripple mutation (Y447F + Y733F + T494V)

Table 3 | Primary antibodies used for immunofluorescence and Western blotting

Antibody	Cat. Number	Research Resource Identifier (RRID)	Vendor	Application	Dilution
IBA1	019-19741	AB_839504	Wako Pure Chemical Industries	Immunofluorescence	1:500
ARR3	AB15282	AB_1163387	Merck KGaA	Immunofluorescence	1:1000
PODXL	AF1556	AB_354858	R&D Systems	Immunofluorescence	1:200
CTNB1	610153	AB_397554	BD Transduction Laboratories™	Immunofluorescence	1:500
Cre	69050-3	AB_10806983	Merck	Immunofluorescence	1:300
HIF2A	AB199	AB_302739	Abcam	Western blotting	1:500
HIF1A	NB100-479	AB_10000633	Novus Biologicals	Western blotting	1:2000
ACTB	A5441	AB_476744	Sigma	Western blotting	1:10000

Figure 1


A
Retina
<0.001
0.003
0.020
0.031
relative expression
Y
O
VEGFA
ANGPTL4
SERPINE1
GNAT2
B
RPE
0.030
0.002
0.001
0.061
RPE65

Figure 2


A
Young/Normal
Normoxia
Old/AMD
Hypoxia
CC
BM
RPE
PS
ONL
B
Hif1a
Hif2a
Slc2a1
relative expression
shCtrl
shHif1
shHif2
Normoxia
Hypoxia
C
shCtrl
shHif1
shHif2
HIF1A
←120 kDa
ACTB
42 kDa
Normoxia
Hypoxia
HIF2A
120 kDa
D
AAV-shHif
GRK1 prom
GFP
shHif1a
VMD2 prom
mCherry
shHif2a
5'miR-E
3'miR-E
AAV-shCtrl
shCtrl
AAV-shHif1
AAV-shHif2

Figure 3


A
Subretinal injection
BM
RPE
SRS
PS
ONL
B
WT + shCtrl
2 wpi
Fundus
OCT
OCT
GFP
mCherry
C
WT + shHif
2 wpi
Fundus
OCT
OCT
GFP
mCherry
D
WT + shCtrl
3wpi
RPE
PS
ONL
INL
GFP / Cherry / DAPI
GFP
mCherry
20μm
E
WT + shHif
3 wpi
GFP / Cherry / DAPI
GFP
mCherry
20μm
F
WT + shCtrl
3 wpi
Retina
RPE
GFP
IBA1
1000μm
mCherry
G
WT + shHif
3 wpi
H
WT
22 wpi
+ shCtrl
+ shHif
RPE
PS
ONL
INL
GCL
50μm
I
scotopic flash
WT + shCtrl
WT + shHif
a-wave amplitude [μV]
scotopic flash
b-wave amplitude [μV]
photopic flash
b-wave amplitude [μV]
stimulus intensity [log(cd*s/m2)]

Figure 4


A
RPE ΔVegfa
CC
BM
RPE
PS
ONL
Vegfa
B
non-transduced area
transduced area
3 wpi
Vegfa / DIC
Cre / DIC
RPE
C
non-transduced area
transduced area
PODXL in choroidal flatmount
PODXL in sections
CC
PODXL
Threshold
Pixel intensity
Distance [µm]
non-transduced area
transduced area
p < 0.0001
Gapsize per 250 µm [µm]
D
RPE ΔVegfa
3 wpi
39 wpi
Fundus
OCT
GFP
Angiography
F
RPE ΔVegfa; morphology
39 wpi
Vegfa fl/fl
RPE ΔVegfa
Vegfa fl/fl + PBS
Vegfa fl/fl + GFP
RPE
PS
ONL
INL
GCL
50µm
E
RPE ΔVegfa; in vivo quantification
39 wpi
Vegfa fl/fl
RPE ΔVegfa
Vegfa fl/fl + PBS
Vegfa fl/fl + GFP
62 64
ON
18 17
56 60
58 57
p= 0.0005
p= 0.0077
ONL thickness [units]
Vegfa fl/fl
RPE ΔVegfa
Vegfa fl/fl + PBS /
Vegfa fl/fl + GFP
G
RPE ΔVegfa; in vitro quantification
39 wpi
ONL thickness
PS length
nasal
temporal
ONL thickness [µm]
PS length [µm]
Distance from ON [µm]
p=0.0065
p<0.0001
Vegfa fl/fl
RPE ΔVegfa
Vegfa fl/fl + GFP
Vegfa fl/fl + PBS

Figure 5


A
Rod ΔVhl
BM
RPE
ONL
Vhl
Rod ΔVhl + shHif
Hif2a
Hif1a
B
Rod ΔVhl
22 wpi
non-injected
+ shCtrl
+ shHif
Fundus
OCT
GFP
mCherry
C
Rod ΔVhl; in vivo quantification
22 wpi
Vhl fl/fl
+ shCtrl
+ shHif
ON
ONL thickness [units]
p<0.0001
p=0.0007
p=0.01
+ shCtrl
+ shHif
Ctrl (Vhl fl/fl)
D
Rod ΔVhl; morphology
22 wpi
Vhl fl/fl
+ shCtrl
+ shHif
RPE
ONL
INL
GCL
50µm

E
Rod ΔVhl; retina
22 wpi
Hif1a
Hif2a
Casp1
Pde6b
p=0.018
p=0.854
p=0.059
p=0.017
relative gene expression
+ shCtrl
+ shHif
F
Rod ΔVhl; RPE / eyecup
22 wpi
Hif1a
Hif2a
Rpe65
p=0.88
p=0.0372
p=0.528
relative gene expression
+ shCtrl
+ shHif

Figure 6


A
RPE ΔVegfa
39 wpi
+ shCtrl
+ shHif
Fundus
OCT
OCT
GFP
mCherry
Fundus
OCT
OCT
GFP
mCherry
B
RPE ΔVegfa; in vivo quantification
39 wpi
+ shCtrl
+ shHif
+ shHif1
+ shHif2
24 24 ON
50 56 ON
35 38 ON
38 43 ON
25 50 75 100 125 150
thickness [units]
p=0.0027
p=<0.0001
p=0.0450
+ shCtrl
+ shHif
+ shHif1
+ shHif2
C
RPE ΔVegfa; morphology
39 wpi
transduced area (nasal)
untransduced area (nasal)
+ shCtrl
+ shHif
+ shHif1
+ shHif2
RPE
ONL
INL
GCL
PS
50μm
D
RPE ΔVegfa; in vitro quantification
39 wpi
ONL thickness
PS length
nasal (transduced)
temporal (non-transduced)
ONL thickness [μm]
PS length [μm]
Distance from ON [μm]
+ shCtrl
+ shHif
+ shHif1
+ shHif2
p<0.0001
p=0.0091
p=0.099
p<0.0001
p=0.0372
p=0.0396
shCtrl
shHif
shHif1
shHif2

Figure 7


A
RPE ΔVegfa
4 wpi
+ shCtrl
+ shHif
Fundus
GFP
mCherry
B
RPE ΔVegfa
61 wpi
C
RPE ΔVegfa
61 wpi
non-transduced area (temporal)
+ shCtrl
+ shHif
RPE
ONL
INL
GCL
50µm
transduced area (nasal)
D
RPE ΔVegfa; in vitro quantification
61 wpi
ONL thickness
PS length
+ shCtrl
+ shHif
ONL thickness [µm]
PS length [µm]
Distance from ON [µm]
p<0.0001
p=0.001
p=0.0006
+ GFP
+ shHif
+ shCtrl